Stocks were indicated marginally lower on Monday morning, with more worries of trade wars after steel and aluminum tariffs. The Dow Jones industrial average was indicated to open under 24,500 and the S&P 500 was indicated to open under 2,685. The bull market is turning nine years old this week, and the one trend that has prevailed has been for investors to buy the pullbacks. Investors have to decide how they want to be positioned for the rest of 2018 and beyond.

24/7 Wall St. reviews dozens of analyst research reports each day of the week to find new ideas for investors and traders alike. Some analyst reports and research reports cover stocks to buy. Others cover stocks to sell or to avoid.

Additional color and commentary has been added on most of the daily analyst reports. The consensus analyst price targets and other valuation metrics are from the Thomson Reuters sell-side research service.

These were the top analyst upgrades, downgrades and other research calls from Monday, March 5, 2018.

AMAG Pharmaceuticals Inc. (NASDAQ: AMAG) was downgraded to Hold from Buy with a $20 target price (versus a $21.00 prior close) at Jefferies. The stock was up 2.4% on Friday but was indicated down 2.9% at $20.40 on Monday. The shares have traded between $11.93 and $25.20 in the past 52 weeks.

AmerisourceBergen Corp. (NYSE: ABC) was reiterated as Buy and the price target was raised to $115 (versus a $93.96 close) at Argus.

Bluebird Bio Inc. (NASDAQ: BLUE) was started with an Outperform rating at William Blair. Shares closed at $206.10 on Friday, in a 52-week range of $74.45 to $222.03.

Cactus Inc. (NYSE: WHD) has an Overweight rating and a $31 price target (versus a $24.66 close) at Barclays. It was started as Overweight with a $32 target price at JPMorgan, and Credit Suisse started it as Outperform with a $31 price target.

Evolus Inc. (NASDAQ: EOLS) was started with a Buy rating and assigned a $24 price target (versus an $11.44 close) at SunTrust Robinson Humphrey. Mizuho started it with a Buy rating and assigned a $21 price target, while JMP Securities started it as Market Perform with a $20 price target.

Foot Locker Inc. (NYSE: FL) closed down over 12% at $40.04 on Friday after disappointing earnings. Pivotal Research maintained the stock as Buy, but its price target was cut to $57 from $65. Telsey Advisory maintained its Outperform rating on Foot Locker, and its target price was cut to $49 from $56. Wedbush Securities maintained its Outperform rating with a $59 price target.

Groupon Inc. (NASDAQ: GRPN) was raised to Equal Weight from Underweight with a $4.40 price target (versus a $4.27 close) at Morgan Stanley.

H&R Block Inc. (NYSE: HRB) was raised to Buy from Neutral at Northcoast Capital. The stock closed down 1.75% at $24.69 on Friday and was indicated up 1.3% at $25.02 on Monday, in a 52-week range of $20.50 to $31.80.

Intrepid Potash Inc. (NYSE: IPI) was raised to Market Perform from Underperform with a $3.75 target price (versus a $3.56 close) at Cowen.

Lifepoint Health Inc. (NASDAQ: LPNT) was downgraded to Market Perform from Outperform with a $52 price target (versus a $46.30 close) at Leerink.

MacroGenics Inc. (NASDAQ: MGNX) was started with a Buy rating and a $38 price target (versus a $28.94 close) at H.C. Wainwright.

Follow @Jonogg on Twitter to receive the daily analyst calls and other market research calls directly on your feed.